Imeglimin is the first clinical candidate in a new chemical class of oral agents called the glimins by the World Health Organization. Imeglimin acts on the three key organs which play an important role in the current anti-diabetic treatment paradigm: the liver, muscles, and the pancreas.1 In several studies conducted to date, imeglimin has demonstrated potential glucose-lowering effects through increased insulin secretion in response to glucose2, increased insulin sensitivity3, and suppression of gluconeogenesis.4 Imeglimin’s mechanism of action also has the potential to prevent diastolic dysfunction567 and to provide protective effects on beta cell survival and function.8

Over a dozen clinical trials have been conducted studying imeglimin with over 1,200 patients with T2D in the U.S., Europe, and Japan, which have met their primary and secondary endpoints, including a statistically significant decrease of HbA1c and fasting plasma glucose versus placebo with a favorable side effect profile.9 Metavant aims to initiate a Phase 3 program in patients with type 2 diabetes and chronic kidney disease (CKD) stages 3b/4 in the US and Europe.


1 Fouqueray et al., J Diabetes Metab 2011, 2:4.
2 Pacini G et al., Diabetes Obes Metab. 2015;17:541-5.
3 Vial et al., Diabetes, 2015;64:2254-2264.
4 Fouqueray et al., J Diabetes Metab 2011, 2:4.
5 Detaille et al. Cell Death Discovery, 2016; 2,15072.
6 Poster #717, European Association for the Study of Diabetes, 12th–16th September 2016, Munich, Germany.
7 Poster #2054, American Diabetes Association, 9th–13th June 2017, San Diego, USA.
8 Poster #00084 World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, 1st–3rd December 2016, Los Angeles, USA.
9 Fouqueray, P. et al. (2013). 36(3), 565–568.